Masimo Co. (NASDAQ:MASI) Given Consensus Rating of "Moderate Buy" by Analysts

Masimo Co. (NASDAQ:MASI - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $194.80.

A number of equities analysts have commented on MASI shares. Needham & Company LLC restated a "hold" rating on shares of Masimo in a research report on Thursday, April 10th. Piper Sandler raised their price objective on shares of Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Wells Fargo & Company raised their target price on shares of Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Finally, Raymond James boosted their price target on Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a report on Friday, December 27th.

Masimo Price Performance

Masimo stock traded down $1.54 during midday trading on Friday, reaching $152.07. 139,235 shares of the company were exchanged, compared to its average volume of 654,249. The firm's 50-day simple moving average is $170.11 and its 200-day simple moving average is $164.63. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The company has a market capitalization of $8.22 billion, a price-to-earnings ratio of 104.88 and a beta of 1.28. Masimo has a 1 year low of $101.61 and a 1 year high of $194.88.

Remove Ads

Masimo (NASDAQ:MASI - Get Free Report) last posted its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. The business had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. On average, analysts anticipate that Masimo will post 4.1 EPS for the current year.

Insiders Place Their Bets

In other news, COO Bilal Muhsin sold 30,000 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the sale, the chief operating officer now owns 24,172 shares in the company, valued at approximately $4,048,568.28. This trade represents a 55.38 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Craig B. Reynolds sold 2,053 shares of the company's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the transaction, the director now owns 16,581 shares of the company's stock, valued at $2,754,601.53. The trade was a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 9.70% of the company's stock.

Hedge Funds Weigh In On Masimo

Several institutional investors and hedge funds have recently bought and sold shares of MASI. Jones Financial Companies Lllp purchased a new stake in Masimo in the fourth quarter worth $27,000. UMB Bank n.a. grew its stake in shares of Masimo by 180.9% in the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock worth $32,000 after acquiring an additional 123 shares during the period. Trust Co. of Vermont bought a new position in shares of Masimo during the 4th quarter valued at $33,000. Blue Trust Inc. lifted its holdings in Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock valued at $33,000 after acquiring an additional 71 shares during the period. Finally, Farther Finance Advisors LLC boosted its holdings in shares of Masimo by 128.9% in the first quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider's stock worth $35,000 after buying an additional 116 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.